SCHEMBL2910658

SCHEMBL2910658

COc1cc(C)c(N)cc1OC1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 2/20 0.47
PDE4A P27815 8/20 0.47
PDE4B Q07343 9/20 0.46
PDE4D Q08499 8/20 0.46
PDE4C Q08493 7/20 0.46
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
GFER P55789 1/20 0.44
PDGFRB P09619 2/20 0.43
PDGFRA P16234 2/20 0.43
CYP3A4 P08684 2/20 0.43
VEGFA P15692 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
CREBBP Q92793 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910790 0.82 NPC1 (0.53) KMT2AMEN1MAPTPDE4APDE4B
SCHEMBL2904851 0.82 PDE4A (0.46) KMT2AMEN1MAPTLMNAPDE4A
SCHEMBL1225409 0.80 POLB (0.61) KMT2AMEN1MAPTPOLBGAA
SCHEMBL29666518 0.80 POLB (0.61) KMT2AMEN1MAPTPOLBGAA
SCHEMBL31378837 0.78 POLB (0.40) KMT2AMEN1MAPTPOLBGAA
SCHEMBL16484217 0.77 PDE4A (0.43) KMT2AMEN1MAPTLMNAPDE4A
SCHEMBL987135 0.75 PDE4A (0.59) PDE4APDE4BPDE4DPDE4CPOLB
SCHEMBL2905188 0.74 PDE5A (0.50) KMT2AMEN1MAPTLMNAPDE4A
SCHEMBL13475207 0.74 PDE4A (0.41) KMT2AMEN1PDE4APDE4BPDE4D
SCHEMBL5704547 0.73 PDE4A (0.57) PDE4APDE4BPDE4DPDE4CPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B KMT2A 1702/4885MEN1 2325/4885MAPT 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.